Reversing Aging
to Treat Disease

Dr. Rando has more than 20 years of experience in aging research and has published over 150 research articles on stem cell aging and tissue repair.

Dr. Rando is a professor of neurology and neurological sciences at Stanford University School of Medicine, where he has worked for 25 years. He is director of the Glenn Laboratories for the Biology of Aging and serves as deputy director of Stanford Center on Longevity. Dr. Rando is also chief of the neurology service and director of the Center for Regeneration, Repair, and Restoration (CTR3) at the Veterans Affairs Palo Alto Health Care System (VAPAHCS), where he previously served as director or the Rehabilitation Research and Development Center of Excellence/REAP and Geriatric Research, Education and Clinical Center. Dr. Rando is a founding director of the Muscular Dystrophy Association clinic at the Stanford Medical Center.

Dr. Rando has been a pioneer and leader in the use of heterochronic parabiosis to study the role of blood and circulating factors in the biology of aging. In 2005 Dr. Rando published a seminal Nature paper demonstrating that factors in young serum can directly reverse many aspects of cellular and tissue aging. Publications from his lab have over 25,000 citations and he has given more than a hundred keynote lectures over the years at a variety of national and international research conferences and high-profile research and medical institutions. He actively serves as editor and board member of numerous scientific journals, including Aging and Disease, PLoS Biology and Aging Cell. 

Dr. Rando is a member of the American Academy of Arts and Sciences and the National Academy of Medicine and a fellow of the American Association for the Advancement of Sciences. Over the course of his career, Dr. Rando has received more than 40 award nominations. He is a former Paul Beeson Physician Faculty Scholar in aging, awarded by the American Federation for Aging Research and a former Ellison Medical Foundation senior scholar in aging. In 2005, he received an NIH Director’s Pioneer Award for his groundbreaking research in stem cell biology. He is also a member of the Advisory Council of the NIH’s National Institute of Aging, and holds board positions at numerous institutions, including Max Planck Institute for Biology of Ageing and the Buck Institute for Age Research.

Dr. Rando serves on the scientific advisory board of several biotechnology and pharmaceutical companies, including Alkahest Inc., Gordian Biotechnology Inc., NDLX Health Sciences, and Novo Biosciences Inc. He previously served on the scientific advisory board of Fate Therapeutics, a $1.2 billion market cap company.

Dr. Rando received a B.A. from Harvard College, and holds an M.D. from Harvard Medical School and a Ph.D. in cell and developmental biology from Harvard University.